首页> 外文期刊>Human gene therapy >Characterization of complete particles (VSV-G/SIN-GFP) and empty particles (VSV-G/EMPTY) in human immunodeficiency virus type 1-based lentiviral products for gene therapy: potential applications for improvement of product quality and safety.
【24h】

Characterization of complete particles (VSV-G/SIN-GFP) and empty particles (VSV-G/EMPTY) in human immunodeficiency virus type 1-based lentiviral products for gene therapy: potential applications for improvement of product quality and safety.

机译:基于人类免疫缺陷病毒1型慢病毒产品的基因治疗中完整颗粒(VSV-G / SIN-GFP)和空颗粒(VSV-G / EMPTY)的表征:提高产品质量和安全性的潜在应用。

获取原文
获取原文并翻译 | 示例
       

摘要

Lentiviral vectors persist in the host and are therefore ideally suited for long-term gene therapy. To advance the use of lentiviral vectors in humans, improvement of their production, purification, and characterization has become increasingly important and challenging. In addition to cellular contaminants derived from packaging cells, empty particles without therapeutic function are the major impurities that compromise product safety and efficacy. Removal of empty particles is difficult because of their innate similarity in particle size and protein composition to the complete particles. We propose that comparison of the properties of lentiviral products with those of purposely expressed empty particles may reveal potential differences between empty and complete particles. For this, three forms of recombinant lentiviral samples, that is, recombinant vesicular stomatitis virus glycoprotein (VSV-G) proteins, empty particles (VSV-G/Empty), and complete particles (VSV-G/SIN-GFP) carrying viral RNA, were purified by size-exclusion chromatography (SEC). The SEC-purified samples were further analyzed by immunoblotting with six antibodies to examine viral and cellular proteins associated with the particles. This study has demonstrated, for the first time, important differences between VSV-G/Empty particles and complete VSV-G/SIN-GFP particles. Differences include the processing of Gag protein and the inclusion of cellular proteins in the particles. Our findings support the development of improved production, purification, and characterization methods for lentiviral products.
机译:慢病毒载体在宿主中持续存在,因此非常适合长期基因治疗。为了促进慢病毒载体在人类中的使用,改善其生产,纯化和表征已变得越来越重要和具有挑战性。除了来自包装细胞的细胞污染物外,没有治疗功能的空颗粒也是危害产品安全性和功效的主要杂质。由于空颗粒的粒径和蛋白质组成与完整颗粒具有先天相似性,因此很难去除空颗粒。我们建议慢病毒产品的性能与有目的表达的空颗粒的性能进行比较可能会揭示空颗粒和完整颗粒之间的潜在差异。为此,需要三种形式的重组慢病毒样品,即重组水泡性口腔炎病毒糖蛋白(VSV-G)蛋白,空颗粒(VSV-G / Empty)和带有病毒RNA的完整颗粒(VSV-G / SIN-GFP)通过大小排阻色谱法(SEC)纯化。通过使用六种抗体的免疫印迹进一步分析SEC纯化的样品,以检查与颗粒相关的病毒和细胞蛋白。这项研究首次证明了VSV-G / Empty颗粒与完整的VSV-G / SIN-GFP颗粒之间的重要区别。差异包括Gag蛋白的加工以及颗粒中包含细胞蛋白。我们的发现支持开发改进的慢病毒产品的生产,纯化和鉴定方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号